Zonisamide and Bupropion for Switching to E-cigarettes

Phase 3, randomised, double-blind trial of zonisamide in nicotine dependence, sponsored by Rose Research Center. Primary endpoints: Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO) at 8 weeks, Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) at 12 weeks and 1 more. Started Dec 2021; status: completed.